Search the Newsreel

Tema ETFs LLC Has $473,000 Stock Position in Expand Energy Corporation $EXE

Tema ETFs LLC significantly reduced its stake in Expand Energy Corporation (NASDAQ:EXE) by 94.3% in the second quarter, selling 86,408 shares and retaining 5,184 shares valued at $473,000. Despite this, institutional investors collectively own 97.93% of the company, and analysts generally maintain a "Moderate …

Dockside LLC Invests $11.64 Million in Expand Energy Corporation $EXE

Dockside LLC has invested $11.64 million in Expand Energy Corporation (NASDAQ:EXE), acquiring 127,698 shares and making it their second-largest portfolio holding. Institutional investors now own 97.93% of the company. Despite some recent analyst downgrades, the consensus rating remains a "Moderate Buy" with an average …

Lexeo Therapeutics (NASDAQ:LXEO) Stock Rating Lowered by Wall Street Zen

Wall Street Zen has downgraded Lexeo Therapeutics (NASDAQ:LXEO) from a "hold" to a "strong sell" rating, despite a broader analyst consensus of "Buy" with an average price target of $18.75. The company's shares opened at $4.84, near its 12-month low, and it reported a …

Lexeo Therapeutics (LXEO): OrbiMed entities disclose combined 5% ownership stake

OrbiMed Advisors LLC and OrbiMed Capital LLC have disclosed a combined 5% ownership stake in Lexeo Therapeutics, Inc. (LXEO). OrbiMed Advisors LLC holds 4.1% of the common stock with shared voting and dispositive power, while OrbiMed Capital LLC holds 1.0% with sole voting and …

Lexeo Therapeutics (LXEO): Paradigm BioCapital reports over 5% beneficial stake

Paradigm BioCapital-related entities and Senai Asefaw, M.D. have reported beneficial ownership in Lexeo Therapeutics, Inc. (LXEO) via a Schedule 13G/A filing. Paradigm BioCapital Advisors LP, Paradigm BioCapital Advisors GP LLC, and Senai Asefaw each beneficially own 4,175,382 shares, representing 5.3% of the class, while …

Crexendo Surpasses 8 Million Users as Global Adoption of Its Cloud Communications Platform Accelerates

Crexendo, Inc. announced that its AI-enhanced UCaaS software platform now supports over 8 million users worldwide, marking a significant milestone. The company has added approximately one million users in the past eight months, and its user base has grown by over 370% since the …

EXEL|Exelixis Inc|Price:50.990|

Farallon Capital (EXEL) discloses 13.99M-share Exelixis stake at $308M cost

Farallon Capital Management, L.L.C., and its affiliated investment partnerships, the Farallon Funds, have disclosed a beneficial ownership of 13,989,010 shares of Exelixis, Inc. (EXEL). This stake represents 5.6% of Exelixis' outstanding common stock and has an approximate net investment cost of $308,124,978. The information …

Barclays Adjusts Expand Energy Price Target to $107 From $110, Maintains Equalweight Rating

Barclays has lowered its price target for Expand Energy (EXE) to $107 from $110, while keeping an Equalweight rating on the stock. This adjustment reflects a recent trend of analysts revising their price targets for Expand Energy, with some increasing and others decreasing their …

Expand Energy agrees to acquire Twin Eagle in a $1.25 billion deal to strengthen its U.S. natural gas platform

Expand Energy is set to acquire Twin Eagle Holdings, N.A., LLC for $1.25 billion to enhance its U.S. natural gas platform. This acquisition will integrate Expand Energy's supply and financial strength with Twin Eagle's marketing platform, creating a fully integrated natural gas company. The …

Expand Energy Corp (EXE) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Expand Energy Corp (EXE), detailing its current price momentum, support and resistance levels, and indicator and moving average signals. It highlights that EXE's stock is trading between a resistance of 100.24 and a support of 87.77, making …

Balyasny Asset Management (LXEO) discloses 7.84M-share Lexeo Therapeutics stake capped at 9.99%

Balyasny Asset Management and its affiliated entities have disclosed a beneficial ownership of 7,844,311 shares of Lexeo Therapeutics, Inc. (LXEO) common stock, representing 9.99% of the outstanding shares. This stake includes shares directly held by Atlas Diversified Master Fund and Atlas Private Holdings, with …

ETFs Investing in Exelon Corporation Stocks

This article provides a comprehensive list of Exchange Traded Funds (ETFs) that hold Exelon Corporation (1EXC) stocks. It details various ETFs, their market value of Exelon holdings, weight percentage, issuer, management style, expense ratio, assets under management (AUM), current price, change, relative volume, and …

Exelon (EXC) Restores Power As Fair Value Still Sits Above The Stock

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Exelon (EXC) is back in focus after its Commonwealth Edison unit restored power to more than 80% of customers affected by severe storms …

CXDO insider plans 30,000-share sale in Nasdaq: CXDO Form 144 filing

David Wang, an insider at Crexendo, Inc. (CXDO), has filed a Form 144 to sell up to 30,000 shares of common stock through Wells Fargo Clearing Services, LLC, with an aggregate market value of $210,000. The filing also indicates Wang's current ownership of 193,366 …

Lexeo Therapeutics (LXEO): Affinity Asset Advisors reports 8.4% beneficial stake

Affinity Asset Advisors, LLC and Michael Cho have reported an 8.4% beneficial stake in Lexeo Therapeutics (LXEO) through an amended Schedule 13G filing. This includes 6,674,913 shares of common stock, with 867,302 shares issuable upon warrant exercise, as of June 30, 2026. The reporting …

TSX:EXE Climbs 1.93% as Extendicare Expands Home Health Platform and Delivers Record Quarterly Revenue

Hennion & Walsh Asset Management Inc. Invests $1.24 Million in Lexeo Therapeutics, Inc. $LXEO

Hennion & Walsh Asset Management Inc. has initiated a new position in Lexeo Therapeutics, Inc. (NASDAQ:LXEO), purchasing 265,697 shares valued at approximately $1.24 million during the second quarter. This investment comes as institutional investors collectively own 60.67% of the company. Lexeo Therapeutics recently reported …

Exelixis (EXEL) Q2 2026 Earnings Call Transcript

Exelixis (EXEL) reported its Q2 2026 earnings, with total revenues reaching $628.7 million, a 10.6% increase year-over-year, driven by cabozantinib sales. The company updated its full-year 2026 revenue guidance downwards due to a more gradual sales ramp in the neuroendocrine tumor indication but reduced …

Annex Advisory Services LLC Makes New Investment in Exelixis, Inc. $EXEL

Annex Advisory Services LLC has acquired a new stake in Exelixis, Inc. (NASDAQ:EXEL), purchasing 25,918 shares valued at approximately $1.41 million during the second quarter. This investment comes as Exelixis reported strong quarterly earnings, surpassing EPS expectations, though revenue slightly missed analyst estimates. Despite …

Exelon Corp (EXC) Earnings Forecast: Future EPS & Revenue Growth Estimates

How Investors May Respond To Exelon (EXC) Balancing Storm Recovery Costs With Steady Utility Earnings

Exelixis, Inc. (EXEL) Stock Forecasts

Argus has lowered its target price for Exelixis Inc. (EXEL) to $56.00, while the current price stands at $50.44. Exelixis is a biopharmaceutical company focused on discovering, developing, and commercializing cancer treatments.

Do Extendicare’s (TSX:EXE) Steady Dividend and Mixed Profits Reveal Its True Capital Priorities?

Exelixis director Mary Beckerle sells $526k in shares

Exelixis director Mary Beckerle sold 9,812 shares of the company's common stock for over $526,000, executed under a Rule 10b5-1 trading plan. This transaction leaves her with 16,079 beneficially owned shares, including RSUs. The sale occurred as Exelixis's stock saw a recent decline but …

Insider Selling: Exelixis (NASDAQ:EXEL) Director Sells $526,511.92 in Stock

Exelixis (NASDAQ:EXEL) Director Mary Beckerle sold 9,812 shares of company stock, valued at $526,511.92, under a pre-arranged Rule 10b5-1 trading plan. This transaction reduced her ownership by 37.9% to 16,079 shares. The biotechnology company recently reported strong quarterly earnings, beating analyst estimates with $0.91 …

Exelixis (EXEL) director Beckerle sells 9,812 shares via Rule 10b5-1 plan

Exelixis director Mary C. Beckerle sold 9,812 shares of common stock on August 10, 2026, at a weighted average price of $53.66 per share, under a pre-arranged Rule 10b5-1 trading plan. Following this transaction, Beckerle's holdings consist of 16,079 shares, which are to be …

Lexeo Therapeutics (NASDAQ:LXEO) Announces Earnings Results, Hits Estimates

Lexeo Therapeutics (NASDAQ:LXEO) announced its latest quarterly earnings, reporting a loss of $0.30 per share, which matched analysts' consensus estimates. Following the announcement, the stock saw a 4.6% increase to $5.00, although it remains significantly below its 12-month high. Analysts maintain a "Buy" rating …

Expand Energy (NasdaqGS:EXE) Stock Forecast & Analyst Predictions

Expand Energy's revenue and earnings are projected to decline over the next three years, with EPS expected to grow by 1.6% per annum. The company recently reaffirmed its production guidance, announced an acquisition of Twin Eagle Holdings for $1.25 billion, and continues to issue …

Lexeo Therapeutics, Inc. (LXEO) Stock Price, News, Quote & History

Benchmark cuts Expand Energy stock price target on lower gas outlook

Benchmark has lowered its price target for Expand Energy (NASDAQ:EXE) stock from $124 to $109, while maintaining a Buy rating, due to a reduced long-term natural gas price assumption. Despite the cut, the firm sees over 10% upside potential and InvestingPro analysis suggests the …

EXE December 2027 Options Begin Trading

Investors in Expand Energy Corp (Symbol: EXE) saw new options begin trading today, for the December 2027 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 492 days …

Expand Energy (NASDAQ:EXE) Given New $109.00 Price Target at Benchmark

Benchmark has lowered its price target for Expand Energy (NASDAQ:EXE) to $109.00 from $124.00, while maintaining a "buy" rating, indicating a potential upside of 10.95%. Despite this reduction and others from various firms, the consensus analyst rating remains a "Moderate Buy" with an average …